General Information of the Drug (ID: M6APDG03820)
Name
IO-202
Status
Phase 1
TTD Drug ID
DM9GO4
Target Gene(s) and Their Upstream m6A Regulator, Together with the Effect of Target Gene(s) in Drug Response
The target genes involved in drug-target interaction (such as drug-metabolizing enzymes, drug transporters and therapeutic targets) and drug-mediated cell death signaling (including modulating DNA damage and repair capacity, escaping from drug-induced apoptosis, autophagy, cellular metabolic reprogramming, oncogenic bypass signaling, cell microenvironment, cell stemness, etc.) could be regulated by m6A regulator(s) and affected their corresponding drug response. You can browse detailed information on drug-related target gene(s) mediated by m6A regulators.
Leukocyte immunoglobulin-like receptor B4 (LILRB4)
Fat mass and obesity-associated protein (FTO)
In total 1 mechanisms lead to this potential drug response
Response Summary Leukocyte immunoglobulin-like receptor B4 (LILRB4) is a therapeutic target for IO-202. The Fat mass and obesity-associated protein (FTO) has potential in affecting the response of IO-202 through regulating the expression of Leukocyte immunoglobulin-like receptor B4 (LILRB4). [1], [2]
References
Ref 1 Targeting FTO Suppresses Cancer Stem Cell Maintenance and Immune Evasion. Cancer Cell. 2020 Jul 13;38(1):79-96.e11. doi: 10.1016/j.ccell.2020.04.017. Epub 2020 Jun 11.
Ref 2 WL-276, an antagonist against Bcl-2 proteins, overcomes drug resistance and suppresses prostate tumor growth. Cancer Res. 2008 Jun 1;68(11):4377-83. doi: 10.1158/0008-5472.CAN-07-6590.